Pure Global
NCT06376526

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

Immuno-consolidation for Newly Diagnosed Multiple Myeloma Using Lack of MRD Negativity After Initial cOmbination Therapy to Pursue Deeper Responses With Linvoseltamab ANd Delay Transplant
Dickran Kazandjian, MD·Phase 2·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Multiple Myeloma
Drug/Device/Intervention
Linvoseltamab
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Dickran Kazandjian, MD
Funder
University of Miami
Location
Miami, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Jun 30, 2024
End date
Jun 30, 2029
Enrollment
28 participants
Primary outcome

Minimal Residual Disease (MRD) Negativity Rate

Summary

The purpose of this study is to determine whether Linvoseltamab therapy in patients with
 newly diagnosed multiple myeloma will convert the disease status from minimal residual
 disease (MRD)-positive to MRD-negative, and increase the length of time that the disease is
 controlled. The researchers also want to find out the effects (good and bad) that
 Linvoseltamab has on participants and the condition.

ICD-10 classifications
Multiple myelomaMultiple myeloma and malignant plasma cell neoplasmsOther myeloid leukaemiaMyeloid leukaemiaOther myelodysplastic syndromes
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06376526
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06376526 through Pure Global AI's free database. This Phase 2 trial is sponsored by Dickran Kazandjian, MD and is currently Not yet recruiting. The study focuses on Multiple Myeloma. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.